Quick Answer
Accustem Sciences Inc. reported Net Income of -$1.51 million for fiscal year 2024.
Accustem Sciences Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net Income | -$1.51M +26.6% |
-$2.05M +45.3% |
-$3.75M -458.7% |
-$670.6K | — |
| Diluted EPS | -$0.13 +27.8% |
-$0.18 +47.1% |
-$0.34 | — | — |
| Total Assets | $50.9K -62.0% |
$133.9K -85.8% |
$939.7K -30.6% |
$1.35M | — |
| Stockholders Equity | -$3.31M -56.9% |
-$2.11M -1413.1% |
-$139.6K -121.4% |
$650.7K -50.3% |
$1.31M |
| R&D Expense | $138.3K -1.0% |
$139.7K -47.7% |
$266.9K +264.0% |
$73.3K | — |
| Operating Income | -$1.51M +26.6% |
-$2.05M +45.3% |
-$3.75M -458.7% |
-$670.6K | — |
| Shares Outstanding | 12.10M +6.6% |
11.35M +0.0% |
11.35M +13.5% |
10.00M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$399.9K | -21.9% | +0.4% |
| Diluted EPS | September 30, 2025 | -$0.02 | +33.3% | +0.0% |
| Total Assets | September 30, 2025 | $1.57M | +1415.4% | -2.5% |
| Stockholders Equity | September 30, 2025 | -$2.91M | +8.9% | -14.8% |
| R&D Expense | September 30, 2025 | $72.7K | +131.5% | +20.8% |
| Operating Income | September 30, 2025 | -$399.9K | -21.9% | +0.4% |
| Shares Outstanding | September 30, 2025 | 16.07M | +41.6% | +0.0% |
- Accustem Sciences Inc. reported Net Income of -$1.51 million for fiscal year 2024.
- Accustem Sciences Inc. showed an increase of +26.6% in Net Income compared to the prior fiscal year.
- Accustem Sciences Inc. reported Diluted EPS of $0.13 per share (loss) for fiscal year 2024.
- Accustem Sciences Inc. showed an increase of +27.8% in Diluted EPS compared to the prior fiscal year.
- Accustem Sciences Inc. reported Total Assets of $50.9 thousand for fiscal year 2024.
- Accustem Sciences Inc. showed a decrease of -62.0% in Total Assets compared to the prior fiscal year.
- Accustem Sciences Inc. reported Stockholders Equity of -$3.31 million for fiscal year 2024.
- Accustem Sciences Inc. showed a decrease of -56.9% in Stockholders Equity compared to the prior fiscal year.
- Accustem Sciences Inc. reported R&D Expense of $138.3 thousand for fiscal year 2024.
- Accustem Sciences Inc. showed a decrease of -1.0% in R&D Expense compared to the prior fiscal year.
- Accustem Sciences Inc. reported Operating Income of -$1.51 million for fiscal year 2024.
- Accustem Sciences Inc. showed an increase of +26.6% in Operating Income compared to the prior fiscal year.
- Accustem Sciences Inc. reported Shares Outstanding of 12.10 million shares for fiscal year 2024.
- Accustem Sciences Inc. showed an increase of +6.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: